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IntegrinPrevious studies have demonstrated both synergistic and opposing effects of Akt and Mek1/2 in various cell
functions and disease states. Furthermore, Akt has been reported to inhibit and activate cRaf/Mek pathway,
suggesting that their mutual interaction and cooperation may be cell type, stimuli and/or context speciﬁc.
While PI3-kinase/Akt and cRaf/Mek pathways have been implicated in the regulation of extracellular matrix
(ECM) remodeling, mutual interactions between these two pathways and their speciﬁc contributions to the
events leading to ECM synthesis and assembly is not clear. We investigated the speciﬁc role of Akt1 and Mek1
in ECM synthesis and assembly by NIH 3T3 ﬁbroblasts and how these effects were reconciled to mediate overall
ECM remodeling. Our study identiﬁed that cooperation between Akt1 and Mek1 is necessary to mediate ECM
synthesis. Whereas Akt1 activation resulted in Mek1 activation as evidenced by increased ERK1/2 phosphoryla-
tion, Mek1 inhibition using U0126 or DN-Mek1 resulted in enhanced Akt1 phosphorylation. Interestingly, both
Akt1 and Mek1 activities were needed for the synthesis and assembly of ECM. The effect of Akt1 and Mek1 on
ECM synthesis was reconciled through the activation of p70 S6-kinase via phosphorylation at T421/S424 and
S411, respectively. Furthermore, Akt1 andMek1 cooperated inmediating ECMassembly via activation of integrin
β1. Together,we show for theﬁrst time that Akt1 andMek1pathways cooperate in the regulation of ECM remod-
eling by the ﬁbroblasts.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Extracellular matrix (ECM) is a non-cellular structural network
composed of mainly proteins such as ﬁbronectin, collagens, laminins
and elastin as well as proteoglycans such as dermatan sulfate and
hyaluronan [1]. Fibroblasts, the major source of ECM, also perform
their assembly during tissue remodeling [2], and are precursors of path-
ologic myoﬁbroblasts that mediate tissue ﬁbrosis [3]. ECM provides the
necessary scaffold to the surrounding cells to group them together and
confer ﬂexibility and strength.
Research from our laboratory has demonstrated the key role of
serine–threonine kinase Akt1 (Protein kinase Bα) in ECM remodeling
in vitro and in vivo. Our studies in Akt1−/−mice revealed that expression
and assembly of collagen matrix in normal skin and during cutaneous
wound healing, aswell as the expression of laminin in the vascular base-
ment membrane are all impaired in the absence of Akt1 gene [4,5].
Pharmacological inhibition of Akt or ablation of Akt1 gene resulted in
impaired ﬁbronectin matrix assembly viamodulation of Rac1 and P21ntal Therapeutics, College of
gents University, Augusta, GA
4.activated kinase pathway [6,7]. Furthermore, secretion of ﬁbronectin
and collagen types I, II and V was also regulated by Akt1 via mTOR
signaling in response to the pro-ﬁbrotic factor transforming growth
factor-β (TGFβ) or agents such as bleomycin [8]. Recently, we also dem-
onstrated that, apart from the pro-ﬁbrogenic role of Akt1 in ﬁbroblasts,
sustained activation of Akt1 leads to myoﬁbroblast differentiation asso-
ciated with enhanced expression of alpha-smooth muscle cell actin
(αSMA) contractile protein through serum response factor (SRF) and
myocardin-mediated pathway [9]. These studies indicated that ﬁne
tuning of Akt1 activity is necessary to maintain ECM homeostasis in
tissues.
Another pathway activated during a ﬁbrogenic response that has
been implicated in ECM remodeling is the cRaf/Mek/ERK1/2 pathway
[10]. However, reports on mutual interactions between cRaf/Mek and
PI3 kinase/Akt pathways are highly conﬂicting. An early study done in
HEK293 cells indicated that Akt is responsible for the direct phosphory-
lation of cRafS259 leading to inhibition of Mek/ERK1/2 pathway [11].
Another study showed that Akt can keep cRaf in an inactive as well as
an active form depending upon the phosphorylation status of another
serine residue (cRafS338) by an unknown kinase that promote its inter-
action with adaptor protein 14-3-3 [12]. Whereas one study indicated
that P21 activated kinase-1 (Pak1) is responsible for the activation
of cRaf signaling in mediating oncogenic transformation in Rat-1
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coupled by phosphorylation of cRafSer259 by Akt1 and cRafSer338 by Pak1
[14]. While many follow-up studies conducted early on have reported
mutual activity inhibition and opposing effects of Akt and cRaf path-
ways in physiology [15,16], most recent studies bymultiple laboratories
[17–20], including ours [14,21] demonstrated a cooperation between
Akt and cRaf/Mek signaling in multiple cellular processes in vitro, and
physiology and pathology in vivo. These reports suggest that the cross-
talk between Akt and cRaf/Mek pathways may be cell, tissue or context
dependent and warrants additional research to investigate the role of
Akt and cRaf/Mek cooperation in multiple cellular and physiological
processes.
In our study,we identiﬁed that cooperation between Akt1 andMek1
pathways is necessary for overall ECM remodeling by the ﬁbroblasts.
Whereas Akt1 was primarily responsible for ECM secretion and the
role of Mek1 was more prominent in ECM assembly, both Akt1 and
Mek1 activities were needed for each of these inter-dependent facets
of ECM remodeling. One of the candidates that reconciled the effects
of Akt1 and Mek1 pathways in the regulation of ECM remodeling
was p70 S6-kinase (p70S6K), which is activated by both Akt1/mTOR
and Mek1/ERK1/2 pathways through phosphorylation at speciﬁc
Threonine421 and Serine424 residues on p70S6K, respectively. On the
other end, Akt1 andMek1 cooperated in activating integrin β1 in medi-
ating ECM assembly. Overall, we report novel insights into the role of
p70S6K in harmonizing the Akt1 and Mek1 pathways in the regulation
of ECM remodeling.
2. Materials and methods
2.1. Reagents, cell lines and antibodies
NIH 3T3 ﬁbroblasts were obtained from ATCC (Manassas, VA) and
maintained in DMEM (HyClone, Logan, UT) supplemented with 10%
fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin
in a 5% CO2 incubator at 37 °C. Primary antibodies against phospho-
AktS473, phospho-MekS217/221, Pan-Mek, phospho-S6 ribosomal
protein235/236, phospho-p70S6KT421/S424, phospho-ERK1/242/44,
phospho-4EBP37/46 and pan-Akt were purchased from Cell Signaling
(Boston, MA). Primary antibodies against phospho-p70S6KSer411 were
purchased from Abcam (Cambridge, MA). Bleomycin and primary anti-
bodies against β-actin and ﬁbronectin were purchased from Sigma (St.
Louis, MO). Anti-collagen-I was purchased from Rockland (Gilbertsville,
PA). All HRP-conjugated secondary antibodies were obtained from Bio-
Rad (Hercules, CA) and Alexa-labeled secondary antibodies were pur-
chased from Life Technologies (Carlsbad, CA). TGFβ was purchased
from R&D (Minneapolis, MN), whereas LY294002 inhibitor, U0126 in-
hibitor, and Rapamycin were purchased from EMDMillipore Bioscience
(San Diego, CA). PF4708671 inhibitor was obtained from Santa Cruz
Biotechnology (Dallas, TX). Adenoviral particles encoding CA-Mek1
and DN-Mek1 were obtained from Cell Biolabs, Inc. (San Diego, CA),
whereas retroviral plasmids encoding CA-Akt1 and DN-Akt1 were gen-
erated in the laboratory [6].
2.2. Virus-mediated transfection
For adenoviral infection, NIH3T3ﬁbroblastswere grown to 75% con-
ﬂuence in 6-well plates. Next, cells were washed with 1× PBS and 1 ml
of medium, supplemented with 10 μg of polybrene, followed by
5 × 108 PFU/ml of adenoviral particles encoding DN-Mek1 (Mek1-
S217A/S221A) or 1 × 108 PFU/ml of adenoviral particles encoding CA-
Mek1 (Mek1-S217E/S221E). After 24 h,mediumwas replaced and incu-
bated for additional 24 h (~95% transfection efﬁciency was obtained).
For retroviral infection, phoenix cells were transfected with pBabe CA-
Akt1 (Myristoylated Akt1) or pBabe DN-Akt1 (Akt1-K179M) plasmids
with puromycin resistance. After 48 h, retroviral particles were collect-
ed and added to NIH 3T3 Fibroblasts in 1 ml of medium, supplementedwith 10 μg of polybrene. After antibiotic selection of stable NIH 3T3 ﬁ-
broblasts, 100% transfection was conﬁrmed by GFP staining. Primary
human foreskin ﬁbroblasts, passages 11–16, were kindly gifted by
Dr. Tatiana Byzova, Cleveland Clinic, Cleveland, OH. Human foreskin
ﬁbroblasts were transfected by retroviral infection and subjected to pu-
romycin selection, and re-infected by adenoviral particles for co-
expression of proteins.
2.3. Analysis of ECM secretion
A modiﬁcation of previously described protocol was used for the
analysis of secreted ﬁbronectin [8]. Fibroblasts, either treated with
5 μM U0126, 5 μM LY294002, 25 nM Rapamycin and/or 10 μM
PF4708671 alone or together with cells transfected with: pBabe empty
vector, CA-Akt1 vector, DN-Akt1 vector, DN-Mek1or CA-Mek1particles,
respectively or in combination of CA-Akt1 with DN-Mek1 or DN-Akt1
with CA-Mek1, were grown in six-well plates in serum-free medium.
Conditioned media were collected after 16 h. Next, cells were lysed
using lysis buffer after treatment with control vehicle (DMSO) or
TGFβ (100 pM). Fibronectin and collagen type I from the conditioned
media was concentrated by TCA precipitation and was re-dissolved in
normal saline, and pH adjusted using NaOH solution. Cell lysates and
conditioned media were subjected to Western analyses of secreted
ECM proteins using speciﬁc antibodies.
2.4. Analysis of ﬁbronectin matrix assembly
Fibronectin matrix assembly was analyzed based on the immuno-
ﬂuorescence staining of insoluble ﬁbronectin ﬁbrils as described previ-
ously [6,7]. Brieﬂy, NIH 3T3 ﬁbroblasts, stably transfected with pBabe
empty vector, CA-Akt1 or DN-Akt1 were co-transfected with Ad-DN-
Mek1 Ad-CA-Mek1, particles, Retro-CA-Akt1 co-transfected with Ad-
DN-Mek1 and Retro-DN-Akt1 co-transfected with Ad-CA-Mek1 parti-
cles, were plated on cell culture chamber slides (Fisher scientiﬁc,
Pittsburgh, PA) at 90–100% of conﬂuence and cultured for the next 8 h
in serum freemedium. Next, cells were ﬁxedwith 2%paraformaldehyde
in 1× PBS for 30 min followed by blocking with 5% BSA for 1 h at room
temperature. The ﬁxed and blocked cells were incubated with primary
antibody against ﬁbronectin (dilution 1:1000) overnight at 4 °C, follow-
ed bywashingwith 1× PBS (3× for 15min each). Next, Alexa Fluor 488-
labeled secondary antibodies were added and incubated room temper-
ature for 1 h (dilution 1:1000). Slides were washed and mounted with
Vectashield (Vector Laboratories). The images were taken using Zeiss
ﬂuorescent microscope (Zeiss Axiovert100M, Carl Zeiss, Germany).
2.5. HUTS-4 binding assay
Activation-dependent ligand HUTS-4 antibodies were used to deter-
mine the activation status of β1 integrins [6,22]. To analyze HUTS-4
binding, serum-starved human foreskin ﬁbroblasts were cultured in
a 96-well plate (85–95% of conﬂuence) and were incubated with
HUTS-4 antibodies (30 μg /ml) for 40 min. Wells were washed with
PBS, ﬁxed in 2% paraformaldehyde and further incubated with anti-
rabbit Alexa 555 antibodies for another 1 h. Plate was then subjected
to quantiﬁcation of ﬂuorescence in a Synergy HT multi-plate reader
with excitation wavelength at 484/20 nm and emission wavelength at
590/35 nm.
2.6. Cell adhesion and spreading assay
Cell adhesion assays were performed as previously described [6].
NIH 3T3 ﬁbroblasts (1 × 105) were suspended in serum-free medium
andwere immediately transferred to ﬁbronectin-coated 12-well plates.
After incubation at 37 °C for 45min, the wells were washed three times
with 1× PBS. Cells were then ﬁxed with 4% paraformaldehyde and
stained with 1% crystal violet solution, and adherent cells were
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spreading cells as quantiﬁed manually and using Image J software.
2.7. Western analysis
Whole cell lysates were prepared using lysis buffer [50mMTris–HCl
(pH= 7.4), 1% TritonX-100, 150 mMNaCl, 1 mM EDTA, 2 mMNa3VO4,
and 1× Complete protease inhibitors (Roche Applied Science,
Indianapolis, IN)]. The protein concentration was measured by the Dc
protein assay (Bio-Rad, Hercules, CA). Western analyses were per-
formed using standard Laemmli's method as done previously [8]. Densi-
tometry was done using NIH Image J software.
2.8. Statistical analysis
All the data are presented as means ± SD. To determine signiﬁcant
differences between treatment and control values, we used either one
way ANOVA for groups of 3 or more, or the Student's two-tailed t test
for studies including 2 independent groups. The signiﬁcance was set at
0.05 levels (marked with symbols wherever data are statistically
signiﬁcant).pan Akt
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44ERK1/2 levels at different time points post TGFβ treatment. (D) NIH 3T3 ﬁbroblasts were tr
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3.1. PI3Kinase/Akt and Mek1/2/ERK1/2 pathways modulate the synthesis
and secretion of ECM proteins
First, we determined the time-course of changes in the phos-
phorylation of Akt and ERK1/2 in response to 100 pM TGFβ up to 16 h
(Fig. 1A–C). While treatment of NIH 3T3 ﬁbroblasts with 100 pM of
TGFβ or 1 mU of bleomycin up to 16 h increased phosphorylation of
Akt, ERK1/2 and ribosomal S6 protein (S6RP; substrate of mTOR), co-
treatment with 5 μM PI3 kinase inhibitor LY294002 inhibited both
TGFβ- and bleomycin-induced phosphorylation of Akt and ERK1/2, sug-
gesting that both Akt and ERK1/2 pathways mediate TGFβ-mediated
function downstream of PI3 kinase activation (Fig. 1D). Whereas our
previous studies have demonstrated the importance of Akt-mTOR path-
way in ECM secretion, in our current study, co-treatment with Mek1/2
inhibitor U0126 signiﬁcantly inhibited the synthesis and secretion of ﬁ-
bronectin and collagen Type I in cell lysates and conditioned media, re-
spectively, associatedwith a decrease in the phosphorylation of Mek1/2
substrate ERK1/2 (Fig. 1E and F). Interestingly, U0126 treatment result-
ed in increased phosphorylation of Akt, but reduced phosphorylation of
S6RP in NIH 3T3 ﬁbroblasts (Fig. 1E).C
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response study of PI3 kinase and Mek inhibitors (LY294002 and
U0126, respectively) on Akt, ERK1/2 and mTOR activity modulation.
Our study revealed that 1–10 μM range of LY294002 signiﬁcantly
inhibited Akt, S6RP and ERK1/2 phosphorylations in a dose-dependent
manner in the presence and absence of TGFβ (Fig. 2A and C). In contrast,
Mek inhibition by 1–50 μM range of U0126, although reduced ERK1/2
and S6RP phosphorylations, resulted in signiﬁcantly increased Akt
phosphorylation in the presence and absence of TGFβ (Fig. 2B and D).
These results suggest the potential involvement of Mek–ERK1/2 path-
way, in addition to Akt, in the activity regulation of mTOR and synthesis
and secretion of ECM proteins.
3.2. Both Mek1 and Akt1 are important for ECM protein synthesis in
ﬁbroblasts
Control and TGFβ-stimulated NIH 3T3 ﬁbroblasts were treated with
mTOR inhibitor rapamycin and/or expressed them with DN-Mek1 in
the presence and absence of stable expression of CA-Akt1. Effect of
rapamycin and Akt1 expression on mTOR activity was determined
through the analysis of phosphorylation of mTOR substrates p4EBP1
and pS6RP (Fig. 3A). In control and TGFβ-stimulated NIH 3T3 ﬁbroblasts,
treatment with rapamycin or expression of DN-Mek1 signiﬁcantly
inhibited expression of ﬁbronectin and collagen type I in cell lysates.
Interestingly, although rapamycin treatment reduced the levels ofA
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bosomal protein and ERK1/2. (C) Graph representing changes in the phosphorylation level of
mean ± SD (n = 3). (D) Graph representing changes in the phosphorylation of Akt and ERK1
Δp b 0.01; #p b 0.05; n = 3).ﬁbronectin and collagen I in the conditioned medium, expression of
DN-Mek1 did not exhibit any signiﬁcant effect on ECM levels in the con-
ditioned medium (Fig. 3A and B). Whereas cells containing CA-Akt1
expressed signiﬁcantly higher levels of ECM (~3 fold) in both the cell ly-
sates and the conditionedmedium, this effect was signiﬁcantly inhibited
by co-expression of DN-Mek1 or treatment with rapamycin. Whereas
rapamycin and DN-Mek1 had only a modest effect on inhibiting CA-
Akt1-mediated ECM expression, a combination of rapamycin treatment
and DN-Mek1 expression exhibited a signiﬁcant additive effect in
inhibiting CA-Akt1-induced ﬁbronectin and collagen I expression
(Fig. 3A and B). Increased levels of p42/44 ERK in cells expressing CA-
Mek1 and increased expression of Mek1 in cells expressing DN-Mek1,
compared to vector control cells is shown in Fig. 3C. Interestingly, al-
though DN-Mek1 expression signiﬁcantly reduced the expression of
ECM proteins in ﬁbroblasts, no signiﬁcant change in either ﬁbronectin
or collagen I levels were observed in the conditioned media in the ab-
sence or presence of TGFβ. Another important ﬁnding from our experi-
ment was that expression of DN-Mek1 in ﬁbroblasts, although reduced
phosphorylation of ERK1/2, it resulted in increased Akt phosphorylation
in control and TGFβ treated cells (Fig. 3A). As observed in the case of
U0126 treatment, expression of DN-Mek1 resulted in partial inhibition
of S6RP phosphorylation despite Akt activation. This effect of DN-Mek1
was also observed in CA-Akt1 expressing ﬁbroblasts (Fig. 3A), thus sug-
gesting the role of Mek1 in the activation of mTOR signaling and subse-
quent regulation of ECM remodeling.B
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1630 A. Goc et al. / Biochimica et Biophysica Acta 1853 (2015) 1626–16353.3. Akt1 and Mek1 differentially regulate ECM secretion and assembly
In our analysis, whereas DN-Mek1 expression in ﬁbroblasts resulted
in reduced ECM levels in the cell lysates, signiﬁcant difference was not
observed in the conditionedmedia collected from DN-Mek1 expressing
ﬁbroblasts, compared to control (Fig. 4A and B). In contrast, whereas
CA-Mek1 expression resulted in reduced ECM levels in the conditioned
medium, a signiﬁcant increase in bothﬁbronectin and collagen Iwas ob-
served in the cell lysate, compared to control (Fig. 4A and B). Similar re-
sults were observed even in the presence of TGFβ stimulus (Fig. 4A and
B). Together, these data suggested speciﬁc roles for Akt1 andMek1 in ﬁ-
broblasts in mediating ECM secretion and assembly, respectively.3.4. Cooperation between Akt1 and Mek1 pathway is necessary for overall
ECM remodeling
We next expressed NIH 3T3 ﬁbroblasts with DN-Akt1, DN-Mek1,
CA-Akt1 and CA-Mek1 alone and in various combinations. Surprisingly,
expression of DN-Mek1 and CA-Mek1 both resulted in increased phos-
phorylation of Akt (Fig. 4A and B). In contrast, the effect of Akt1 on ECM
levels in the cell lysate and the conditioned media was as expected.
Whereas DN-Akt1 expression in ﬁbroblasts resulted in signiﬁcant
reduction in the levels of ECM proteins in both cell lysates and
the conditioned media, expression of CA-Akt1 resulted in increased
ECM production. Although DN-Mek1 resulted in increased Akt1phosphorylation in NIH 3T3 ﬁbroblasts, expression of CA-Akt1 signiﬁ-
cantly increased ERK1/2 phosphorylation, which was reduced in DN-
Akt1 ﬁbroblasts (Fig. 4A). Interestingly, whereas both CA-Mek1 and
CA-Akt1 resulted in increased phosphorylation of mTOR substrate
S6RP and inactive isoforms of Akt1 andMek1 inhibiting S6RP phosphor-
ylation, effect of DN-Akt1 expression on S6RP was reversed with co-
expression of CA-Mek1. In contrast, increased phosphorylation of S6RP
with CA-Akt1 expression was blunted upon co-expression of DN-
Mek1. This suggested that Mek1-mediated effect on ECM remodeling
is mediated through its ability to modulate S6RP phosphorylation inde-
pendent of Akt1 and mTOR pathways. Also, Akt1-mediated effect on
ECM assembly, but not secretion,may be due to the ability of Akt1 to ac-
tivate Mek1 pathway.
3.5. p70 S6-kinase (p70S6K) reconciles Akt1 and Mek1 pathways in the
regulation of ECM secretion
Next, we examined if Mek1 is able to activate p70S6K via a mecha-
nism different from the Akt1-mTOR pathway. We speciﬁcally looked
into changes in the phosphorylation of Serine 411 residue on p70S6K,
which has also been shown to be involved in its activation [23,25].
Our analysis showed that while DN-Mek1 had no effect on pT421/
S424p70S6K levels, it signiﬁcantly reduced pS411p70S6K levels, which
in turn, correlated with the phosphorylation of S6RP phosphorylation
(Fig. 5A). As expected, treatment with p70S6K inhibitor, PF4708671,
inhibited the expression levels of collagen I and ﬁbronectin in both
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This effect was at par with mTOR inhibition with rapamycin (Fig. 5A
and B). Increased ECM secretion as a result of CA-Akt1 expression in ﬁ-
broblasts, was partially inhibited by treatment with PF4708671, thus
suggesting that p70S6K is a connecting link between Akt1-mTOR and
Mek1 pathways in the regulation of ECM secretion.3.6. Akt1 and Mek1 cooperate in mediating ﬁbronectin matrix assembly
Wenext performed ﬁbronectinmatrix assembly assay in NIH 3T3 ﬁ-
broblasts expressing DN-Mek1, CA-Mek1, DN-Akt1, CA-Akt1 as well as
CA-Mek1 in combination with DN-Akt1, and DN-Mek1 in combination
with CA-Akt1. We observed that expression of CA-Akt1 signiﬁcantly
enhanced ﬁbronectin matrix assembly; an effect that is impaired with
DN-Akt1 expression (Fig. 6A and B). Similarly, whereas expression of
CA-Mek1 enhanced ﬁbronectin matrix assembly, expression of DN-
Mek1 signiﬁcantly impaired the process (Fig. 6A and B). Interestingly,
while a modest inhibition of ﬁbronectin matrix assembly was observed
in cells co-expressing CA-Mek1 and DN-Akt1 as compared to CA-Mek1
expressing controls, only a partial rescue in ﬁbronectinmatrix assembly
was observed in cells co-expressing DN-Mek1 and CA-Akt1 (Fig. 6A and
B), suggesting that Mek1 activity is necessary for the overall ﬁbronectin
matrix remodeling.3.7. Akt1 and Mek1 cooperation mediated integrin activation
We next determined if Akt1–Mek1–p70S6K signaling is involved in
the regulation of integrin β1 function in ﬁbroblasts. Our results indicat-
ed that ﬁbroblasts expressing either CA-Akt1 or CA-Mek1 resulted in
enhanced adhesion on to ﬁbronectin, a ligand for integrin β1 (Fig. 7A
and B). Interestingly, an additive effect of CA-Mek1 over the effect of
CA-Akt1 on integrin activation was not observed in cells co-expressing
CA-Akt1 and CA-Mek1. Next, we subjected human foreskin ﬁbroblasts
transfected with various Akt1 and Mek1 plasmids, either alone or in
combinations, and in the presence and absence of p70S6K inhibitor, to
determine their effect on HUTS-4 binding, a highly speciﬁc assay for
integrin β1 activation. In our results, whereas cells expressing DN-
Akt1 or DN-Mek1 exhibited impaired HUTS-4 binding, cells expressing
CA-Akt1 or CA-Mek1 exhibited enhanced HUTS-4 binding compared
to vector control cells (Fig. 7C). Treatment of cells co-expressing CA-
Mek1 and CA-Akt1 with p70S6K inhibitor PF4708671 signiﬁcantly
inhibited cell adhesion, spreading and HUTS-4 binding indicating the
role of p70S6K in the process (Fig. 7A-C).
Collectively, our results clearly demonstrated that Akt1 and Mek1
synergize their effects in mediating ECM secretion and assembly, and
that activation of p70S6K via phosphorylation at T421/S424 and S411 by
Akt1 and Mek1/ERK1/2, respectively, is at least in part responsible for
their cooperation in mediating ECM secretion and assembly (Fig. 7D).
Fig. 5. p70S6 kinase synergizes Akt1 and Mek1-mediated synthesis and secretion of ECM proteins by the ﬁbroblasts. (A) Western blot images of cell lysates and conditioned media from
either NIH 3T3 ﬁbroblasts expressing either CA-Akt1 or DN-Mek1 and/or co-treatedwith rapamycin (mTOR inhibitor) or PF4708671 (p70S6 kinase inhibitor), followed by treatmentwith
DMSO or 100 pM TGFβ in serum free medium. (B) Bar graphs showing densitometry analysis of cell lysates and conditioned media for the synthesized and secreted ﬁbronectin and col-
lagen I expressing either CA-Akt1 or DN-Mek1 and/or co-treatedwith rapamycin or PF4708671, followed by treatmentwith DMSOor 100 pMTGFβ in serum freemedium. Data presented
as mean ± SD (*p b 0.001; Δp b 0.01; #p b 0.05; n = 3).
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Fibronectin and collagens, the major elements of the ECM, interact
with integrins to form the meshwork that determines the structure
and function of tissues such as skin, brain, lung, and heart [26]. Synthe-
sis, secretion and assembly of ECM proteins are the crucial steps in the
process of ECM remodeling.We [4,6–8] and others [27,28] have demon-
strated the integral role of Akt1/mTOR signaling in ECM secretion. Apart
from the Akt1/mTOR pathway, cRaf/Mek1/2 signaling has also been im-
plicated in the regulation of ECM remodeling, particularly in the assem-
bly of ECM proteins [10]. However, reports on the mutual interactions
and activitymodulationbetweenAkt and cRaf/Mek1/2 pathways in var-
ious in vitro and in vivo settings have been conﬂicting [11,12]. Thus, fur-
ther investigation is necessary to determine the net effect of individual
and/or combined activitymodulation of Akt andMek1/2 pathways in ﬁ-
broblast will have on ECM remodeling. In the current study, we demon-
strated for the ﬁrst time that Akt1 synergizes with Mek1 in the
regulation of ECM secretion and assembly by the ﬁbroblasts in vitro,
and this cooperation is mediated through p70 S6K and integrin β1.
Akt was ﬁrst reported to inhibit cRaf activity through direct phos-
phorylation at S259 leading to subsequent inhibition of Mek1/2/ERK1/2
pathway in HEK293 cells [11]. Follow-up studies from various laborato-
ries conﬁrmed that cRaf and Akt pathways mutually inhibit their activ-
ities in response to certain growth factors and often elicit opposite
effects under physiological and pathological [15,16,29]. These reports
questioned if at all any cooperation between Akt and Mek pathways is
possible in physiology or pathology or whether the cooperation ormutual inhibition of these pathways is cell or context dependent. But,
an elegant study from Joseph Avruch laboratory identiﬁed the sequence
of events involved in the activity modulation of cRaf [12]. This study,
which provided insights on the complex nature of cRaf activity regula-
tion by Ras, Akt and other unknown kinases, also revealed that Akt
can both inhibit and activate cRaf signaling depending on the status of
other signaling pathways. Accordingly, although cRafS259 phosphoryla-
tion by Akt inhibited cRaf activity, phosphorylation of cRafS338 by an un-
known kinase promoting its interaction with adaptor protein 14-3-3
prevailed over the inhibitory effect of Akt, andwas necessary for the sta-
ble activation of cRaf. The kinase responsible for the phosphorylation of
cRafS338 was later identiﬁed to be Pak1 [30].
Numerous studies demonstrated the cooperation between Akt and
cRaf/Mek signaling in various cellular, physiological and pathological
processes including adaptive angiogenesis and cancer [17–20]. We
showed that phosphorylation of cRafS338 by Pak1 in Rat-1 ﬁbroblasts ac-
tivates cRaf and is necessary for the coupling of Akt1 and cRaf pathways
in mediating oncogenic transformation [14,31]. We also showed that
combined inhibition of Akt and Mek pathways had signiﬁcantly higher
effect on the inhibition of prostate cancer cell motility, proliferation
and colony formation as compared tomonotherapy [21]. These ﬁndings
suggest that mutual activity modulation and cooperation between Akt
and Mek pathways may be cell, tissue or context speciﬁc. Recently, co-
operation between Akt and Mek pathways have also been reported in
colorectal [32], rhabdomyosarcoma [33] and many other cancers [34,
35]. While most of these studies are focused on cancers where different
signaling pathways are already deregulated, details regarding mutual
Fig. 6. Akt1/Mek1 axis signaling regulates overall ﬁbronectinmatrix assembly by the ﬁbroblasts. (A) Representative ﬂuorescent pictures of NIH 3T3 ﬁbroblasts expressing either CA-Akt1,
DN-Akt1, CA-Mek1, DN-Mek1 or a combination of CA-Akt1withDN-Mek1 or DN-Akt1with CA-Mek1 treatedwith 100 pMTGFβ (or DMSO) in serum freemedium. After 8 h, cellular layers
were immunostained for ﬁbronectin and probed with Alexa 488. (B) Bar graph showing NIH-ImageJ based quantitative analysis of assembled ﬁbronectin by the ﬁbroblast layers express-
ing either CA-Akt1, DN-Akt1, CA-Mek1, DN-Mek1, or a combination of CA-Mek1 with DN-Akt1 or DN-Mek1 with CA-Akt1 treated with 100 pM TGFβ (or DMSO) in serum free medium.
Data presented as mean ± SD (*p b 0.001; #p b 0.05; n = 3).
1633A. Goc et al. / Biochimica et Biophysica Acta 1853 (2015) 1626–1635activity regulation between Akt1 and Mek1 in many physiological pro-
cesses are only emerging.
Whereas increased ERK1/2 activity in the mouse endothelial cells is
achieved through down regulation of PI3 kinase activity or by suppress-
ing Akt1 activity [29], same study indicated activation of ERK1/2 in a
zebra ﬁsh model promoting arteriogenesis via inhibition of PI3 kinase/
Akt pathway. In contrast, a recent study in a tumor model implicated
the role of ERK-2 in the re-activation of Akt pathway [36]. In another
study, PI3 kinase/Akt and Mek/ERK1/2 pathways did not inﬂuence
each other's activity, but co-targeting them inhibited uveal melanoma
cell proliferation [37]. Interestingly, our study revealed that an increase
or decrease in Akt1 activity, both results in enhanced ERK1/2 phosphor-
ylation. Similarly, a decrease in Mek1/2 activity via pharmacological
(U0126) or genetic approaches or increase inMek1 activity, both result-
ed in a signiﬁcant increase in Akt phosphorylation. While the mecha-
nisms leading to this interesting cross-talk between Akt1 and Mek1 is
not clear from our current study, our data however demonstrate that
both these signaling pathways are activated together in response to
TGFβ and cooperate in the modulation of ECM remodeling.
It is not clear how the effects of Akt1 and Mek1/2 cooperation are
reconciled in mediating ECM remodeling. From our past studies, we
know that Akt1 utilizes mTOR for the synthesis of ECM proteins [8]
and activates integrin β1 [6] in mediating assembly of ECM proteins.
Hence, we sought to determine if Mek–ERK1/2 pathway can cooperate
with Akt1 in activating mTOR and integrin β1 signaling in mediatingECM secretion and assembly, respectively. While inhibition of mTOR
with rapamycin had no effect on ERK1/2 phosphorylation, genetic and
pharmacological inhibition of Mek1 reduced phosphorylation of
S6RP, one of the secondary substrates of mTOR, but not 4EBP1, a direct
substrate of mTOR. This indicated thatMek1, although did not inﬂuence
mTOR activity, may be responsible for the activation of a downstream
substrate of mTOR, thus cooperating with Akt1 in regulating ECM
remodeling.
Since S6RP is phosphorylated by p70S6K, an mTOR substrate, we
next determined if Akt1 and Mek1 have independent ways to activate
this kinase. A major known mechanism for the activation of p70S6K is
by its phosphorylation at residues T421/S424 bymTOR [24]. In addition
to this, phosphorylation of another residue implied in p70S6K activation
of S411 [38], and the kinase that is responsible for this phosphorylation
is yet to be identiﬁed.Nevertheless, there is a report that cRaf/Mek path-
way may be responsible for the phosphorylation of S411 on p70S6K
[25]. Our study showed that whereas DN-Mek1 inhibition resulted in
a decrease in S411 p70S6K phosphorylation, expression of CA-Mek1 re-
sulted in increased S411p70S6Kphosphorylation. Furthermore, speciﬁc
inhibition of p70S6K resulted in reduced expression of ﬁbronectin and
collagen I by the ﬁbroblasts. These results demonstrated that Akt1 and
Mek1 reconciled their effects on ECM secretion through activation of
p70S6K.
Another interesting observation from our study is that, although
CA-Mek1 expression in ﬁbroblasts resulted in increased ﬁbronectin
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signiﬁcantly lesser. This usually happens when there is increased
integrin activation subsequently leading to increased conversion of
soluble ECM proteins into insoluble ﬁbers attached to the cells [39,40].
Our study revealed that while activation of both Akt1 and Mek1 result-
ed in increased ﬁbronectin matrix assembly, and HUTS-4 binding, acti-
vation of Mek1 in DN-Akt1 expressing ﬁbroblasts signiﬁcantly rescued
the defects in ECMassembly. Since integrinβ1 is necessary for ﬁbronec-
tin matrix assembly [6] via involving Rac1/P21 activated kinase-1
(Pak1) pathway [7], our studies reveal the importance ofMek1, in addi-
tion to Akt1, in the process. Our ﬁndings support an important observa-
tion from another group on the role of p70S6K in the activation of Rac1
and cdc42 in cytoskeletal remodeling and integrin activation [41]. Over-
all, we demonstrate the cooperation betweenAkt1 andMek1 in the reg-
ulation of ECM secretion and assembly through activation of p70S6K
and integrin β1, respectively. We suggest that co-targeting Akt1 and
Mek1 for ECM-related diseases may be more effective as compared to
monotherapy. However, validation of the results from our in vitro ex-
periments in vivo using suitable animal models will be necessary to
strengthen this conclusion.
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